# Bio Green Med Solution, Inc.: financial statements, quarterly

BGMS · Nasdaq · CIK 1130166 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bgms.md) · [Financials](/companies/bgms/financials.md) · [Filings](/companies/bgms/filings.md) · [Insiders](/companies/bgms/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bgms/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [16.0](/filings/0001558370-24-015349.md) | [31.0 d](/filings/0001493152-25-025179.md) | [29.0](/filings/0001641172-25-010270.md) | [4.0](/filings/0001641172-25-023648.md) | [10.0](/filings/0001493152-25-022388.md) | [0.0 d](/filings/0001493152-26-013669.md) | not reported | not reported | [81.0](/filings/0001493152-25-022388.md) | [(81.0) d](/filings/0001493152-26-013669.md) | [743](/filings/0001493152-26-023800.md) | [336](/filings/0001493152-26-038393.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [5,236](/filings/0001558370-24-015349.md) | [3,518 d](/filings/0001493152-25-025179.md) | [2,802](/filings/0001641172-25-010270.md) | [2,023](/filings/0001641172-25-023648.md) | [950](/filings/0001493152-25-022388.md) | [880 d](/filings/0001493152-26-013669.md) | [822](/filings/0001641172-25-010270.md) | [68.0](/filings/0001641172-25-023648.md) | [5.0](/filings/0001493152-25-022388.md) | [(47.0) d](/filings/0001493152-26-013669.md) | not reported | not reported |
| Selling, general and administrative | $k | [1,625](/filings/0001558370-24-015349.md) | [1,873 d](/filings/0001558370-25-004331.md) | [1,582](/filings/0001558370-24-008159.md) | [1,625](/filings/0001558370-24-012271.md) | [1,237](/filings/0001558370-24-015349.md) | [948 d](/filings/0001558370-25-004331.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(6,845)](/filings/0001558370-24-015349.md) | [(5,360) d](/filings/0001493152-25-025179.md) | [(4,355)](/filings/0001641172-25-010270.md) | [(3,644)](/filings/0001641172-25-023648.md) | [(2,177)](/filings/0001493152-25-022388.md) | [(1,828) d](/filings/0001493152-26-013669.md) | [(4,214)](/filings/0001493152-26-023800.md) | [(1,249)](/filings/0001493152-26-038393.md) | [(992)](/filings/0001493152-25-022388.md) | [(1,082) d](/filings/0001493152-26-013669.md) | [(246)](/filings/0001493152-26-023800.md) | [(418)](/filings/0001493152-26-038393.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [(668)](/filings/0001558370-24-015349.md) | [(422) d](/filings/0001493152-25-025179.md) | [(1,354)](/filings/0001641172-25-010270.md) | [(412)](/filings/0001641172-25-023648.md) | [(210)](/filings/0001493152-25-022388.md) | [1,194 d](/filings/0001493152-26-013669.md) | not reported | [2.0](/filings/0001493152-26-038393.md) | [0.0 d](/filings/0001493152-25-022388.md) | [5.0 d](/filings/0001493152-26-013669.md) | [30.0](/filings/0001493152-26-023800.md) | [9.0](/filings/0001493152-26-038393.md) |
| Net income | $k | [(6,032)](/filings/0001558370-24-015349.md) | [(5,271) d](/filings/0001493152-25-025179.md) | [(2,946)](/filings/0001493152-25-022388.md) | [(3,257)](/filings/0001493152-25-022388.md) | [(1,957)](/filings/0001493152-25-022388.md) | [(3,052) d](/filings/0001493152-26-013669.md) | [(81.0)](/filings/0001493152-26-038393.md) | [(1,318)](/filings/0001493152-26-038393.md) | [(988)](/filings/0001493152-25-022388.md) | [(611) d](/filings/0001493152-26-013669.md) | [(197)](/filings/0001493152-26-038393.md) | [(405)](/filings/0001493152-26-038393.md) |
| Diluted EPS | $ per share | not reported | not reported | [(2.27)](/filings/0001641172-25-010270.md) | [(172.18)](/filings/0001641172-25-023648.md) | [(43.80)](/filings/0001493152-25-022388.md) | not reported | [0.00](/filings/0001641172-25-010270.md) | [(0.98)](/filings/0001641172-25-023648.md) | [(1.31)](/filings/0001493152-25-022388.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | [(2.27)](/filings/0001641172-25-010270.md) | [(172.18)](/filings/0001641172-25-023648.md) | [(43.80)](/filings/0001493152-25-022388.md) | not reported | [0.00](/filings/0001641172-25-010270.md) | [(0.98)](/filings/0001641172-25-023648.md) | [(1.31)](/filings/0001493152-25-022388.md) | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | period not labelled (2024-03-11) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [3,378](/filings/0001493152-25-025179.md) | [3,400](/filings/0001558370-24-003713.md) | [2,798](/filings/0001558370-24-008159.md) | [6,000](/filings/0001558370-24-012271.md) | [2,982](/filings/0001558370-24-015349.md) | [3,137](/filings/0001493152-26-013669.md) | [3,450](/filings/0001641172-25-010270.md) | [4,275](/filings/0001641172-25-023648.md) | [3,838](/filings/0001493152-25-022388.md) | [3,505](/filings/0001493152-26-038393.md) | [3,339](/filings/0001493152-26-023800.md) | [3,790](/filings/0001493152-26-038393.md) |
| Current assets | $k | [7,444](/filings/0001493152-25-025179.md) | not reported | [4,835](/filings/0001558370-24-008159.md) | [7,707](/filings/0001558370-24-012271.md) | [4,913](/filings/0001558370-24-015349.md) | [3,674](/filings/0001493152-26-013669.md) | [3,714](/filings/0001641172-25-010270.md) | [4,383](/filings/0001641172-25-023648.md) | [6,444](/filings/0001493152-25-022388.md) | [6,256](/filings/0001493152-26-038393.md) | [5,622](/filings/0001493152-26-023800.md) | [5,969](/filings/0001493152-26-038393.md) |
| Total assets | $k | [8,805](/filings/0001493152-25-025179.md) | not reported | [6,165](/filings/0001558370-24-008159.md) | [8,190](/filings/0001558370-24-012271.md) | [5,381](/filings/0001558370-24-015349.md) | [4,094](/filings/0001493152-26-013669.md) | [3,734](/filings/0001641172-25-010270.md) | [4,401](/filings/0001641172-25-023648.md) | [8,158](/filings/0001493152-25-022388.md) | [8,185](/filings/0001493152-26-038393.md) | [7,564](/filings/0001493152-26-023800.md) | [7,854](/filings/0001493152-26-038393.md) |
| Current liabilities | $k | [8,161](/filings/0001493152-25-025179.md) | not reported | [8,350](/filings/0001558370-24-008159.md) | [7,186](/filings/0001558370-24-012271.md) | [6,351](/filings/0001558370-24-015349.md) | [6,268](/filings/0001493152-26-013669.md) | [663](/filings/0001641172-25-010270.md) | [760](/filings/0001641172-25-023648.md) | [1,002](/filings/0001493152-25-022388.md) | [1,332](/filings/0001493152-26-038393.md) | [796](/filings/0001493152-26-023800.md) | [692](/filings/0001493152-26-038393.md) |
| Total liabilities | $k | [8,198](/filings/0001493152-25-025179.md) | not reported | [8,371](/filings/0001558370-24-008159.md) | [7,191](/filings/0001558370-24-012271.md) | [6,351](/filings/0001558370-24-015349.md) | [6,268](/filings/0001493152-26-013669.md) | [672](/filings/0001641172-25-010270.md) | [770](/filings/0001641172-25-023648.md) | [1,062](/filings/0001493152-25-022388.md) | [1,343](/filings/0001493152-26-038393.md) | [804](/filings/0001493152-26-023800.md) | [694](/filings/0001493152-26-038393.md) |
| Shareholders' equity | $k | [607](/filings/0001493152-26-013669.md) | not reported | [(2,206)](/filings/0001493152-25-022388.md) | [999](/filings/0001493152-25-022388.md) | [(970)](/filings/0001493152-25-022388.md) | [(2,174)](/filings/0001493152-26-038393.md) | [3,062](/filings/0001493152-26-038393.md) | [3,631](/filings/0001493152-26-038393.md) | [7,096](/filings/0001493152-25-022388.md) | [6,842](/filings/0001493152-26-038393.md) | [6,760](/filings/0001493152-26-038393.md) | [7,160](/filings/0001493152-26-038393.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(4,036) d](/filings/0001558370-24-015349.md) | [(3,910) d](/filings/0001493152-25-025179.md) | [(483)](/filings/0001641172-25-010270.md) | [(3,084) d](/filings/0001641172-25-023648.md) | [(3,067) d](/filings/0001493152-25-022388.md) | [(1,356) d](/filings/0001493152-26-013669.md) | [(3,247)](/filings/0001493152-26-023800.md) | [(1,056) d](/filings/0001493152-26-038393.md) | [(434) d](/filings/0001493152-25-022388.md) | [(33.0) d](/filings/0001493152-26-013669.md) | [(278)](/filings/0001493152-26-023800.md) | [(352) d](/filings/0001493152-26-038393.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001558370-24-015349.md) | [0.0 d](/filings/0001493152-25-025179.md) | not reported | not reported | [0.0 d](/filings/0001558370-24-015349.md) | not reported | not reported | not reported | not reported | not reported | [1.0](/filings/0001493152-26-023800.md) | [0.0 d](/filings/0001493152-26-038393.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.4](/filings/0001558370-22-017410.md) | [10.0](/filings/0001558370-23-009443.md) | [10.1](/filings/0001558370-23-014533.md) | [12.3](/filings/0001558370-22-017410.md) | [12.5](/filings/0001558370-23-009443.md) | [12.6](/filings/0001558370-23-014533.md) | [0.0](/filings/0001493152-25-022388.md) | [0.4](/filings/0001493152-26-023800.md) | [1.4](/filings/0001493152-26-038393.md) | [1.9](/filings/0001493152-25-022388.md) | [5.5](/filings/0001493152-26-023800.md) | [5.6](/filings/0001493152-26-038393.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,622,794 at 2026-08-11, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038393.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.